Aripiprazole is a promising therapeutic agent for the treatment of ME/CFS that is suggested to reduce microglial activation and associated neuroinflammation via TRPM7 [66]. The gene discussed is TRPM7; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.